interval 0.85-1.51; P = 0.39). Early treatment toxicity was acceptabie, with only seven patients developing tansient decase in performance status. The accerated radiotherapy regimen was logistically feasible and acceptable to patients, carers and staff. Treatment time was reduced without apparent increase in early toxicity and there was no loss of survival benefit The effectiveness and convenience of a short accelerated rgimen makes this a suitable alternative to a 6 week course of radiotherapy in patients with high-grade ghoma. However, a full randomised trial comparing conventional and acceklrated radiotherapy may be required as proof of equivalence.
yword. malignant glioma; accelerated radiotherapy; survival Radiotherapy continues to be the mainstay of treatment of patients with high-grade glioma. It prolongs survival and usually maintains quality of life by retaining or inproving neurological function for the duration of tumour control. Conventional radiotherapy schedules test in randomised studies involve a protracted course of irradiation usually to a dose of 60 Gy in 6 weeks. The treatment is given in doses s< 2 Gy per fraction to avoid late normal tissue damage to the central nervous system (CNS), which is highly fractionation dependent.
While in terms of survival a radiotherapy treatment schedule of 60 Gy in 6 weeks is considered optimal (Chang et al., 1983; Bleehen et al., 1991) , the overaD survival of patients with high-grade glioma remains poor, and the purpose of such a protracted high-dose irradiation schedule is largely palliative. In patients destined to survive less than 6 months, who constitute 30% of high-grade glioma patients in an average cohort, 6 weeks' treatment represents 25% or more of remaining life, and this may not be acceptable to patients, relatives and physicans.
Treatment time can be shortened without reducing the biologically effective tumour dose either by reducing the number of fractions and increasing the dose per fraction (hypofractionation) or by giving the same number of fractions treating more than once a day (accelerated fractionation). The former approach may lead to an increased risk of late normal tissue damage to the brain unless the total radiation dose is reduced. The latter regimen in which multiple fractions are given each day at conventional dose per fraction, is also not without disadvantages. Repair of radiation damar in normal tissue may be incomplete in the short time interval between fractions (Ang et al., 1992) , and this may increase the risk of normal tissue toxicity. The logistics of twie-daily treatment also imposes strain on the normal functioning of the radiotherapy department and requires assigned We set out to examine the efficacy and toxicity of accelerated twice-daily radiotherapy in a prospective singlearm study. The results were compared with a matched cohort of patients treated with conventional daily irradiation selected from the MRC BR2 study (Bleehen et al., 1991) on the basis of known prognostic factors (Table I) (Kernohan and Sayre, 1952) . Thirty-nine patients had high-grade tumours not otherwise specified. The presurgical Karnofsky performance status ranged from 10 to 100 (median 90) and preradiotherapy status was 40-100 (median 90). The follow-up of surviving patients ranged from 2 months to 37 months (median 9 months).
Before Figure 2 . There is a suggestion of a slightly different survival pattern, with the study patients having a higher death rate in the first 12 months; however, the survival curves beyond this point are similar, and the overall log-rank comparison gave a P-value of 0.39. The hazard ratio was 1.13, with 95% confidence limits 0.85-1.51. In the second analysis, only those patients treated before the end of 1992 were included (84 patients), together with their matched controls. The results were very similar, with a hazard ratio of 1.12 (95% CI 0.8-1.53).
DiSaOw
Radiotherapy emnains the most effective treatment modality in patients with high-grade glioma (Brada, 1989) , although (Bleehen et al., 1991 We conclude that in patients with high-grade glioma radiotherapy treatment time can be reduced from 6 to just over 3 weeks without a marked increase in toxicity or loss of survival benefit. The short overall survival in these patients precludes any definite conclusion about the long-term safety of high-dose accelerated irradiation. There are logistic problems in this approach which require reorganisation of treatment machine time and occasionally provision of day care or in-patient facilities for patients unable to attend twice daily. This and the overall higher number of fractions have clear financial implications for the service. Nevertheless, in our experience accelerated radiotherapy is feasible and acceptable to patients, staff and carers and has become an available treatment for selected patients who wish to complete therapy in a shorter time.
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